| Literature DB >> 36109082 |
Casper Webers1,2, Astrid van Tubergen3,2, Harald E Vonkeman4,5, Annelies Boonen3,2.
Abstract
OBJECTIVE: To investigate whether work productivity in patients with spondyloarthritis (SpA) changed following the onset of the COVID-19 pandemic.Entities:
Keywords: COVID-19; Epidemiology; Spondyloarthritis
Mesh:
Year: 2022 PMID: 36109082 PMCID: PMC9478431 DOI: 10.1136/rmdopen-2022-002447
Source DB: PubMed Journal: RMD Open ISSN: 2056-5933
Characteristics of patients with a work assessment in the pre-pandemic year
| Variable | Total (n=204) |
| Age, years | 50.8 (10.7) |
| Male, n (%) | 97 (47.6) |
| High education, n (%) | 97 (47.6) |
| Employed, n (%) | 126 (61.8) |
| Current/former smoker, n (%) | 87 (42.9) |
| Diagnosis, n (%) | |
| axSpA | 109 (54.5) |
| pSpA | 23 (11.5) |
| PsA | 62 (31.0) |
| IBD-associated SpA | 3 (1.5) |
| uSpA | 3 (1.5) |
| Uveitis (ever), n (%) | 33 (16.5) |
| IBD (ever), n (%) | 25 (12.5) |
| Psoriasis (ever), n (%) | 84 (42.0) |
| ASDAS | 2.2 (1.0) |
| BASDAI (0–10) | 4.2 (2.4) |
| Patient global assessment | 4.0 (2.8) |
| Current medication use, n (%) | |
| NSAID | 115 (56.4) |
| csDMARD | 69 (33.8) |
| bDMARD | 120 (58.8) |
| tsDMARD | 2 (1.0) |
Values are mean (SD), unless stated otherwise.
ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; pSpA, peripheral spondyloarthritis; SpA, spondyloarthritis; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.
Work impairment at pre-pandemic and postonset assessments
| Pre-pandemic* | Post- onset* | p† | Change (post versus pre)* | |
| Employed patients with pre-assessment and post-assessment (n=108) | ||||
| Overall work impairment (0%–100%) | 27.0 (29.9), | 37.0 (35.8), | <0.01 | +9.9 (28.5), |
| Absenteeism (0%–100%) | 7.1 (21.2), | 16.2 (33.5), | 0.02 | +9.1 (33.4), |
| Presenteeism (0%–100%) | 23.2 (25.4), | 25.8 (27.4), | 0.08 | +3.2 (18.4), |
| All employed patients (n=123 (pre), 120 (post))‡ | ||||
| Overall work impairment (0%–100%) | 27.6 (30.9), | 35.5 (35.6), | N/A§ | N/A§ |
| Absenteeism (0%–100%) | 9.1 (25.0), | 15.4 (33.1), | N/A§ | N/A§§ |
| Presenteeism (0%–100%) | 22.1 (24.7), | 24.8 (27.0), | N/A§ | N/A§ |
*Values expressed as mean (SD) and median (IQR).
†For comparison of post-onset versus pre-pandemic value.
‡This includes patients who completed only one assessment (either pre-pandemic or post-onset).
§No comparison between pre-pandemic and post-onset values, as some patients only completed one of both assessments.
N/A, not applicable.
Univariable and multivariable generalised estimating equation analysis (ASDAS model)
| Univariable | Multivariable | Multivariable | |||||||
| Variable | B | 95% CI | p | B | 95% CI | p | B | 95% CI | p |
| Age (years) | 0.26 | −0.04 to 0.55 | 0.09 | 0.02 | −0.40 to 0.45 | 0.92 | 0.17 | −0.26 to 0.60 | 0.43 |
| Male gender | −6.78 | −13.58 to 0.02 | 0.05 | −0.93 | −10.39 to 8.53 | 0.85 | −2.68 | −12.41 to 7.06 | 0.59 |
| High education | −7.91 | −14.70 to −1.12 | 0.02 | N/A† | N/A† | ||||
| ASDAS | 12.46 | 10.45 to 14.48 | <0.01 | 13.08 | 11.05 to 15.11 | <0.01 | 10.51 | 7.10 to 13.91 | <0.01 |
| BASDAI (0–10) | 7.73 | 6.87 to 8.58 | <0.01 | ‡ | ‡ | ||||
| Patient global assessment (0–10) | 5.55 | 4.89 to 6.21 | <0.01 | ‡ | ‡ | ||||
| NSAID, current | −0.30 | −5.11 to 4.52 | 0.90 | § | § | ||||
| csDMARD, current | 4.76 | −1.20 to 10.72 | 0.12 | § | § | ||||
| bDMARD/tsDMARD, current | −2.47 | −7.19 to 2.24 | 0.30 | § | § | ||||
| Time, post-onset versus pre-pandemic* | 5.32 | 1.82 to 8.82 | <0.01 | 9.57 | 5.63 to 13.51 | <0.01 | 1.49 | −5.39 to 8.36 | 0.67 |
Variables that were possibly associated with the outcome in univariable analysis (p<0.10) were considered for multivariable analysis. Next, these were retained in multivariable models if they were significantly associated with the outcome (p<0.05). Age, gender and the primary variable of interest (time, post-onset vs pre-pandemic) were always included.
*Binary time-varying variable, indicating whether an assessment took place after onset of pandemic versus pre-pandemic (primary variable of interest). As patients were followed up over time, they could have both pre-pandemic assessments (before March 2020, coded 0) and post-onset assessments (after March 2020, coded 1).
†Used for stratification.
‡Due to collinearity, ASDAS, BASDAI and Patient global assessment were not included in the same model.
§Not associated with outcome in univariable analysis.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; N/A, not applicable; NSAID, non-steroidal anti-inflammatory drug; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.